NightHawk Radiology goes public
NightHawk Radiology Holdings announced Oct. 5 that it will hold an initial public offering with the intention of raising more than $86 million, according to a press release from the company’s corporate headquarters.
NightHawk Radiology Holdings announced Oct. 5 that it will hold an initial public offering with the intention of raising more than $86 million, according to a press release from the company's corporate headquarters.
The offsite/off-hours radiology interpretation service based in Coeur d'Alene, ID, will trade its common stock on the Nasdaq under the ticker symbol "NHWK."
NightHawk plans to use IPO proceedings to expand its business and pay down corporate debt. The company reported losses of nearly $8 million for the second quarter of 2005. The statement filed with the U.S. Securities and Exchange Commission did not specify the number of shares nor estimated price, however.
Morgan Stanley, Banc of America Securities, Piper Jaffray, SG Cowen & Co., and Montgomery & Co. will underwrite the IPO.
NightHawk's U.S.-trained and board-certified radiologists provide diagnostic imaging interpretations to 347 customers in 693 hospitals in the U.S. from reading facilities in Sydney, Australia, and Zurich, Switzerland.
The company's move will help improve patient care by having nighttime readings performed by radiologists who are awake in Sydney or Zurich, said Dr. William G. Bradley, professor and chair of radiology at the University of California, San Diego. Bradley is a NightHawk's stockholder and board member.
For more information from the Diagnostic Imaging archives:
Teleradiologists must tread carefully in legal mine field
Legislation tackles offshore teleradiology
New rules for offshore reads may hit rads at home
Necessity provided breeding ground for international teleradiology
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Burnout in Radiology: Key Risk Factors and Promising Solutions
June 9th 2025Recognizing the daunting combination of increasing imaging volume and workforce shortages, these authors discuss key risk factors contributing to burnout and moral injury in radiology, and potential solutions to help preserve well-being among radiologists.
